知镜 Cognispect · 医学文献与研究工作台

The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification.

Ayalasomayajula S, Bajwa EK, Cornell AG, Loureiro MJ, Kim SS, DiBello JR, Sterner E, Chen R, Younis IR.
Clinical and translational science · 2026-08-01 · PMID 42535727

文献摘要

Pulmonary hypertension (PH) is a complex disorder associated with significant morbidity and mortality. PH is characterized by an elevated pulmonary vascular load, leading to right ventricular dysfunction and remodeling, with right heart failure and premature death if left untreated. PH is classified into five groups (WHO Groups 1-5) based on etiology and pathophysiology. Group 1 PH, known as pulmonary arterial hypertension (PAH), has seen recent therapeutic advances with life-extending treatments, including a new therapeutic option that targets the underlying vascular abnormalities. PAH treatment guidelines now emphasize early diagnosis, risk stratification, and targeting multiple pathophysiologic pathways with upfront combination therapy. In contrast to PAH treatment, strategies for other forms of PH remain limited and focus on managing pathophysiologic processes outside the pulmonary vasculature, including left heart disease (Group 2), lung disease and/or hypoxia (Group 3), or pulmonary artery obstructions (Group 4). Nevertheless, advances in research have introduced novel therapeutic targets and investigational agents, offering hope for future expanded treatment options. In this review, we explore recent advances in PH treatments, highlighting the developments poised to expand the therapeutic landscape for this complex disease.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。